Open AccessCurrent Development of Anti-Cancer Drug S-1
Author(s) -
P Chhetri,
Archana Giri,
Subarna Shakya,
Binaya Sapkota,
Pramod Kc
Publication year - 2016
Publication title -
journal of clinical and diagnostic research
Language(s) - Uncategorized
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2016/19345.8776
Subject(s) - tegafur , dihydropyrimidine dehydrogenase , prodrug , toxicity , medicine , capecitabine , pharmacology , drug , fluorouracil , cancer , thymidylate synthase , colorectal cancer
S-1 is a novel oral fluoropyrimidine derivative, widely used for treating gastric, pancreatic, lung, head, neck and breast carcinomas. It is designed to enhance the clinical utility of an oral fluoropyrimidine and is associated with low gastrointestinal toxicity. S-1 consists of three pharmacological agents (at a molar ratio of 1:0.4:1)-Tegafur (FT), a prodrug of 5-Fluorouracil (5-FU), 5-Chloro-2-4-Dihydroxypyridine (CDHP), which inhibits the activity of Dihydropyrimidine Dehydrogenase (DPD) and Oxonic Acid (Oxo), which reduces Gastrointestinal (GI) toxicity of 5-FU. The present article reviews the current development of clinical study of S-1.